CAR-T therapies that are being developed by Bristol Myers Squibb and Janssen have all hit targets in early-mid-stage trials. Increasing hopes of new treatment options for difficult to treat blood cancers. Johnson & Johnson’s Janssen unveiled initial results from the Phase Ib/II CARTITUDE-1 study assessing the efficacy and safety of JNJ-68284528 (JNJ-4528) – an investigational B cell
According to a new report, the UK is ahead compared to the rest of Europe for early-stage clinical research into new medicines and vaccines, with more than 600 commercial clinical trials taking place in the NHS. The first annual report into clinical trials created by the Association of the British Pharmaceutical Industry (ABPI), stated that the UK is a
The saddest aspect of life right now is that science gathers knowledge faster than society gathers wisdom.
Our latest CPIA report features analysis on the Biotechnology sector. Clinical Professionals Group CEO, Yvette Cleland comments: “The UK biotech businesses focused within research and experimental development have risen by 65% since 2016 and the Golden Triangle of London/Oxford and Cambridge accounts for 35% of this concentration of companies. Annual investment reached 2.2 billion in
GSK announce promising results from a study conducted in partnership with non-profit scientific research organisation IAVI, that is investigating the efficacy of the company’s tuberculosis (TB) vaccine in HIV-negative adults with latent TB infection. The study was conducted across 11 sites throughout Kenya, South Africa and Zambia, which are all TB-endemic regions, and enrolled over
A pioneering clinical trial is set to investigate the use of cannabidiol (CBD) in people with Parkinson’s-related psychosis. Parkinson’s UK will be partnering with scientists at King’s College London in the first large-scale trial which aims to provide preliminary evidence for the safety and efficacy of CBD to alleviate the symptoms of Parkinson’s-related psychosis, characterised by hallucinations and delusions.
According to a new analysis that uses market capitalisation as a benchmark, Takeda has recently broken into the list of top 20 publicly traded innovative pharma companies after its $62 billion merger with Shire earlier this year. According to the analysis from GlobalData, Takeda’s market cap grew to $63.4 billion in Q1 this year as
GSK announced results from its PRIMA Phase III trial, in which niraparib was studied as a maintenance therapy in women with first-line ovarian cancer following a response to platinum-based chemotherapy. The data showed that the drug resulted in a 38% reduction in the risk of disease progression or death in the overall population, driven by
Novartis announced positive results from its Cosentyx focused PREVENT trial, advancing the drug in potential new indication for patients with axial spondyloarthritis. The phase III study met its 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA), showing a considerable and clinically meaningful reduction in disease activity. Novartis has also submitted
Our latest CPIA report features analysis and UK and EU vacancy data in the “Human Resources and Talent” sector. Clinical Professionals Group CEO, Yvette Cleland comments: Life sciences cost per hire will continue to rise at a rate of 7% per annually, talent pools continue to constrict and 85% of jobs that will exist in
IR35 rules are designed to stop tax avoidance by workers who provide services to clients via a limited company rather than as employees. A contractor operating through a Limited company but otherwise practically operating as an employee is considered to be a “disguised employee”. HMRC stated there is evidence that contractors in the pharmaceutical industry